A detailed history of Financial Gravity Asset Management, Inc. transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Financial Gravity Asset Management, Inc. holds 4 shares of ARWR stock, worth $104. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4
Previous 8 50.0%
Holding current value
$104
Previous $244,000 47.95%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Jun 26, 2024

SELL
$27.21 - $39.48 $108 - $157
-4 Reduced 50.0%
4 $127,000
Q4 2023

Jun 26, 2024

SELL
$21.2 - $31.03 $21 - $31
-1 Reduced 11.11%
8 $244,000
Q3 2023

Nov 15, 2023

SELL
$26.2 - $36.08 $707 - $974
-27 Reduced 75.0%
9 $0
Q2 2023

Aug 08, 2023

BUY
$25.16 - $41.38 $276 - $455
11 Added 44.0%
36 $171,000
Q1 2023

May 12, 2023

SELL
$23.68 - $38.51 $378 - $616
-16 Reduced 39.02%
25 $196,000
Q4 2022

Feb 15, 2023

SELL
$28.0 - $40.56 $7,168 - $10,383
-256 Reduced 86.2%
41 $182,000
Q3 2022

Nov 03, 2022

SELL
$29.63 - $48.31 $3,644 - $5,942
-123 Reduced 29.29%
297 $256,000
Q2 2022

Aug 05, 2022

SELL
$27.79 - $50.61 $3,668 - $6,680
-132 Reduced 23.91%
420 $272,000
Q1 2022

May 13, 2022

SELL
$39.62 - $69.97 $12,123 - $21,410
-306 Reduced 35.66%
552 $356,000
Q4 2021

Feb 11, 2022

BUY
$58.09 - $82.51 $49,376 - $70,133
850 Added 10625.0%
858 $519,000
Q3 2021

Nov 12, 2021

BUY
$58.38 - $84.96 $467 - $679
8 New
8 $62,000
Q4 2019

Feb 28, 2020

SELL
$28.14 - $73.01 $14,829 - $38,476
-527 Closed
0 $0
Q3 2019

Oct 15, 2019

BUY
$26.26 - $34.86 $13,839 - $18,371
527 New
527 $15,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.76B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Financial Gravity Asset Management, Inc. Portfolio

Follow Financial Gravity Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.